Abstract #4983

Diffusion Basis Spectrum Imaging (DBSI): Successful in vivo Use to Assess Axonal Protection in Mouse Optic Neuritis treated with Fingolimod

Tsen-Hsuan (Abby) Lin¹, Rui-Meng Yang^1,2, Jie Zhan ^1,3, Chunyu Song⁴, Peng Sun¹, Michael Wallendorf⁵, Anne H Cross^6,7, and Sheng-Kwei Song^1,4,7

¹Radiology, Washington University School of Medicine, St Louis, MO, United States, ²Radiology, Guangzhou Medical University, Guangzhou, China, ³Radiology, The First Affiliated Hospital of Nanchang University, Nanchang, China, ⁴Biomedical Engineering, Washington Univerisyt is St. Louis, St Louis, MO, United States, ⁵Biostatistics, Washington University School of Medicine, St Louis, MO, United States, ⁶Neurology, Washington University School of Medicine, St Louis, MO, United States, ⁷Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, United States

We previously introduced diffusion basis spectrum imaging (DBSI) to noninvasively assess coexisting pathologies in central nervous system (CNS) tissues.Previously, we showed in multiple sclerosis (MS) spinal cord specimens and mice with experimental autoimmune encephalomyelitis (EAE), the main animal model of MS, that DBSI reflected coexisting white matter pathologies in CNS. Fingolimod, a disease-modifying treatment approved for relapsing MS, is thought to preserve axons. In the current study, we employed longitudinal DBSI to noninvasively assess fingolimod treatment efficacy in EAE mouse optic nerve, followed by histological validation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here